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httpicense.Abstract Myocardial infarction (MI) continues to be a major public health problem in the world.
Statins exhibit cardio-protective effects by several mechanisms beyond their lipid lowering activity.
Quercetin is a natural ﬂavonoid that possesses signiﬁcant anti-oxidant and antiinﬂammatory activ-
ities. The present study aimed to investigate the effects of pretreatment with atorvastatin (10 mg/kg)
and quercetin (50 mg/kg), as well as their combination on isoprenaline-induced MI in rats. Markers
chosen to assess cardiac damage included serum activity of creatine kinase-MB (CK-MB) and
serum level of cardiac troponin-I (cTn-I), as well as oxidative stress and inﬂammatory biomarkers
including serum levels of C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-a), and inter-
leukin-10 (IL-10) as well as cardiac contents of lipid peroxides, reduced glutathione (GSH), and
nitrite. Furthermore, ECG monitoring and histological examinations of cardiac tissues were done.
Isoprenaline increased serum CK-MB activity and cTn-I level as well as inﬂammatory and oxidative
stress biomarkers. In addition, it produced ST-segment elevation and degenerative changes in heart
tissues. Pretreatment with atorvastatin suppressed signiﬁcantly the elevated levels of cTn-I, CRP,
TNF-a, and IL-10 in serum coupled with reduction in cardiac lipid peroxides; however, it increased
cardiac nitrite content. Quercetin decreased isoprenaline-induced changes in oxidative stress and
inﬂammatory biomarkers with marked improvement in ECG and histopathologic alterations. Com-
bination of quercetin with atorvastatin resulted in similar protective effects. In conclusion, quercetin
can be regarded as a promising cardio-protective natural agent in MI alone or combined with ator-
vastatin.
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Myocardial infarction (MI) is the acute condition of necrosis
of the myocardium that occurs as a result of imbalance be-
tween coronary blood supply and myocardial demand.1
Inﬂammation is a key process involved in mediating myocar-
dial tissue damage after an ischemic event. Neutrophils inﬁl-
trate the infarcted area where they can promote myocardialaculty of Pharmacy, Cairo University.
3.03.001
36 M.A. Zaafan et al.cell damage through the release of proteolytic enzymes and the
production of reactive oxygen species (ROS). Inﬂammation
may also increase the risk of recurrent ischemic events by
destabilizing atherosclerotic plaques and making them prone
to rupture.2
Isoprenaline, a b-adrenoceptor agonist, has been reported
to produce MI in large doses; upon auto-oxidation, isoprena-
line generates highly cytotoxic free radicals known to stimulate
the peroxidation of membrane phospholipids causing severe
damage to the myocardial membrane. Hence, it is widely used
as a model to produce MI in rats.3,4
Atorvastatin is a cholesterol-lowering agent that acts by
competitively inhibiting the rate limiting enzyme of choles-
terol biosynthesis, 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoA) reductase. Statins prevent hypercholesterolemia, a
major risk factor in the development of coronary heart
disease and stroke.5 In addition, recent data have indicated
that statins protect the myocardium against ischemic
injury.6
Quercetin is a natural anti-oxidant, producing its effects
by inhibiting lipid peroxidation through blockade of the en-
zyme xanthine oxidase, chelating iron, and directly scaveng-
ing hydroxyl and superoxide anion radicals.7,8 Quercetin
has also potent anti-inﬂammatory potential.9 In addition, it
has been shown to inhibit inducible nitric oxide synthase
(iNOS) expression and nitric oxide (NO) production, which
further accounts for its anti-inﬂammatory activity.10
The present study aimed to investigate the effects of pre-
treatment with atorvastatin, quercetin or their combination
on isoprenaline-induced MI in rats. Parameters chosen to as-
sess myocardial damage and protective effects of test agents
included serum creatine kinase-MB (CK-MB) activity as well
as levels of cardiac troponin-I (cTn-I), tumor necrosis factor-
alpha (TNF-a), interleukin-10 (IL-10), and C-reactive pro-
tein (CRP). In addition, ECG monitoring and histologic
examination of heart tissues as well as the determination
of cardiac lipid peroxides, reduced glutathione (GSH), and
nitrite contents were done.2. Materials and Methods
2.1. Animals
Male Wistar albino rats weighing 150–200 g were used in the
present study. They were purchased from the Egyptian Orga-
nization for Biological Products and Vaccines (Cairo, Egypt)
and were allowed free access to water and standard pellet
diet. Rats were kept under constant conditions with 12/12 h
light/dark cycles and were housed in plastic cages in the ani-
mal house at October University for Modern Sciences and
Arts (MSA University). The study was carried out according
to the guidelines of the Ethics Committee, Faculty of Phar-
macy, Cairo University.2.2. Drugs and chemicals
Isoprenaline hydrochloride and quercetin were purcashed
from Sigma–Aldrich (MO, USA); whereas atorvastatin was
obtained from Pﬁzer (Egypt). All other chemicals used were
of analytical grade.2.3. Induction of myocardial infarction
MI was induced in rats by subcutaneous injection of 100 mg/
kg isoprenaline hydrochloride dissolved in saline once daily
for two successive days. The selected route and dose were cho-
sen from published literatures.11,122.4. Experimental design
Rats were randomly allocated into ﬁve groups (n= 8). The
ﬁrst two groups received 1% Tween 80 (p.o.) for 14 days and
served as normal and control groups, respectively. The remain-
ing three groups received atorvastatin (10 mg/kg; p.o.), querce-
tin (50 mg/kg; p.o.), and their combination, respectively for
14 days. All groups except the normal one received isoprena-
line (100 mg/kg; s.c.) in the last 2 days of treatment.
Twenty-four hours after the last treatment, animals were
anesthetized with urethane (1.5 g/kg; i.p.) for ECG monitor-
ing. Thereafter, blood samples were collected from the
retro-orbital plexus for serum separation and estimation of
CK-MB activity as well as cTn-I, CRP, TNF-a, and IL-10 lev-
els. Rats were then sacriﬁced by decapitation and the hearts
were rapidly isolated, washed with ice-cold saline and cut into
two equal halves. One half was homogenized in phosphate buf-
fer (pH 7.4) to prepare 10% (w/v) homogenate that was used
for the estimation of cardiac lipid peroxides, GSH and nitrite
contents, while the other half was preserved in 10% formalin
for histologic examination.2.5. ECG monitoring
Anesthetized rats were placed in the supine position on a
board and ECG was recorded continuously with standard arti-
fact free lead II (right forelimb to left hind limb). Needle elec-
trodes were inserted subcutaneously into paw pads of each rat,
and connected to Biocare ECG 101 (Shenzhen Biocare Elec-
tronics Co., Ltd., China). The ECG was measured to deter-
mine duration and amplitude of the P wave, QRS complex,
and ST segment alterations.2.6. Biochemical assays
The activity of CK-MB in serum was determined using
Stanbio CK-MB diagnostic kit (USA). Serum troponin-I
level was measured by enzyme linked immunoassay (ELISA)
technique using a standard kit (Glory Science Co., Ltd,
USA).
Lipid peroxidation in cardiac tissues was estimated by the
determination of thiobarbituric acid reactive substances con-
tent that was evaluated as malondialdehyde (MDA) in heart
homogenate using a standard kit purchased from Biodiagnos-
tic (Egypt). Cardiac GSH content was determined using a
commercial kit (Biodiagnostic, Egypt). Cardiac nitrite was
determined as an index of nitric oxide (NO) content in heart
homogenate using a commercial kit (Biodiagnostic, Egypt).
Serum TNF-a and IL-10 were determined by ELISA tech-
nique using standard kits (RayBiotech, Inc., USA). Serum
CRP was measured using a speciﬁc immunoassay kit (Immu-
nospec Corporation, CA, USA).
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Autopsy samples were taken from heart of rats from different
groups and ﬁxed in 10% formalin prepared in saline. Washing
was done in tap water then serial dilutions of alcohol were used
for dehydration. Specimens were cleared in xylene and embed-
ded in parafﬁn for 24 h. Parafﬁn bees wax tissue blocks were
prepared for sectioning at four microns by a slide microtome.
Sections were deparafﬁnized and stained by hematoxylin and
eosin (H&E) stains for histopathologic examination using the
electric light microscope.
2.8. Statistical analysis
Data were expressed as mean ± SEM. Comparisons between
means of different groups were carried out using one-way
analysis of variance (ANOVA) followed by Tukey–Kramer
multiple comparisons test. The level of signiﬁcance was taken
as p< 0.05. SPSS statistical software package, version 16
(SPSS Inc., Chicago, IL), was used to carry out all statistical
tests.
3. Results
3.1. Effect of atorvastatin, quercetin, and their combination on
ECG on isoprenaline-induced myocardial infarction in rats
Subcutaneous injection of isoprenaline for two successive days
induced MI represented by positive T wave, ST segment eleva-
tion, and a decrease in R wave amplitude as compared to the
normal group (Fig. 1). Pretreatment with atorvastatin, querce-
tin or their combination resulted in a reduction in the ST seg-
ment elevation with an increase in R wave amplitude as
compared to the isoprenaline group (Fig. 1).
3.2. Effect of atorvastatin, quercetin and their combination on
biochemical changes that associate isoprenaline-induced
myocardial infarction in rats
Isoprenaline increased serum CK-MB activity and cTn-I level
by 52.5% and 349.44%, respectively as compared to the nor-
mal group. Pretreatment with atorvastatin suppressed only
the elevated cTn-I level by 49.51% as compared to the isopren-
aline group. Quercetin pretreatment decreased serum CK-MB
activity and cTn-I level by 26% and 64.68%, respectively as
compared to the isoprenaline group. Moreover, pretreatment
with atorvastatin and quercetin decreased serum cTn-I level
by 60.65% (Fig. 2A and B).
Isoprenaline increased cardiac MDA and nitrite contents
by 39.3% and 161.2%, respectively with a parallel decrease
in GSH content by 42.84% as compared to normal rats. Pre-
treatment with atorvastatin decreased MDA by 17.6% and in-
creased the nitrite content by 26.9% as compared to
isoprenaline group. On the other hand, pretreatment with
quercetin decreased MDA and nitrite content by 21.3% and
24.0%, respectively with a parallel increase in GSH content
by 43.4% as compared to the isoprenaline group, while pre-
treatment with atorvastatin combined with quercetin resulted
in a signiﬁcant decrease in MDA and nitrite contents by
18.1% and 35.6%, respectively coupled with an increase inGSH content by 41.7% as compared to isoprenaline group
(Table 1).
Serum levels of CRP, TNF-a and IL-10 increased signiﬁ-
cantly in rats injected with isoprenaline by 87.7%, 62.6%
and 49.1%, respectively as compared to the normal group.
Pretreatment of rats with atorvastatin produced a signiﬁcant
decrease in serum levels of CRP, TNF-a and IL-10 by
30.1%, 22% and 31.4%, respectively as compared to the iso-
prenaline group. Pretreatment with quercetin signiﬁcantly de-
creased serum levels of CRP and TNF-a by 34.9% and
28%, respectively as compared to the isoprenaline group;
meanwhile, pretreatment with atorvastatin combined with
quercetin produced a signiﬁcant decrease in serum levels of
CRP, TNF-a and IL-10 by 38.8%, 32.8% and 37.5%, respec-
tively as compared to the isoprenaline group (Table 2).
3.3. Effect of atorvastatin, quercetin or their combination on
histopathologic changes that associate isoprenaline-induced
myocardial infarction in rats
Hearts from rats injected with isoprenaline showed multiple
focal areas of myocardial cell degeneration with edema and
inﬂammatory cells inﬁltration. A marked improvement was
noticed in rats pretreated with quercetin. On the other hand,
pretreatment with atorvastatin or its combination with querce-
tin resulted in mild improvement of heart tissues as compared
to the isoprenaline group (Fig. 3).
4. Discussion
In the current study, MI was induced in rats by subcutaneous
administration of isoprenaline in a dose of 100 mg/kg for two
successive days. It has been reported that isoprenaline admin-
istration in high doses to animals produces ‘infarct like’ lesions
in the heart similar to those present in MI in humans.13
Mechanisms proposed to explain isoprenaline-induced car-
diac damage are varied and include generation of highly cyto-
toxic free radicals, increased calcium overload, and
mitochondrial injury or dysfunction.14,15 Hence in the present
study, the increase in cardiac MDA content (an indicator for
lipid peroxidation) and the decrease in cardiac GSH content
in isoprenaline group could be expected. The current results
are in line with the work of other investigators.3,4,16
Isoprenaline-generated free radicals are known to initiate
peroxidation of membrane-bound polyunsaturated fatty acids
leading to damage of the structural and functional integrity of
the myocardium with consequent changes in membrane per-
meability.14 Myocyte death or altered membrane permeability
causes the cytosolic contents to eventually enter the systemic
circulation, where they may be detected as markers of the
ischemic heart disease. This accounts for the elevation of ser-
um activity of CK-MB and serum level of cTn-I in the current
experiment several hours following isoprenaline administra-
tion which is in accordance with previous reports.4,13,17
Inﬂammation is a key process involved in mediating myo-
cardial tissue damage after an ischemic event. In the current
study, isoprenaline produced an increase in the serum levels
of CRP and the pro-inﬂammatory cytokine TNF-a, an effect
that is in accordance with the work of other investigators.18,19
The infarcted region undergoes local necrosis and myocyte
apoptosis resulting in complement activation, free radicals
Figure 1 Lead II ECG trace pattern of: (A) Normal rat showing regular ECG pattern with deﬁned P, QRS, and T waves; (B)
Isoprenaline control rat showing positive T wave, ST segment elevation, and decreased R wave amplitude; (C) Atorvastatin-treated rat
showing a decrease in ST segment elevation and an increase in R wave amplitude; (D) Quercetin-treated rat, and (E)
Atorvastatin + quercetin-treated rat showing a marked decrease in ST segment elevation and an increase in R wave amplitude.
Figure 2 Effect of oral atorvastatin (10 mg/kg), quercetin (50 mg/kg), and their combination on serum creatine kinase-MB (CK-MB)
activity (A) and cardiac troponin-I (cTn-I) level (B) in isoprenaline-induced myocardial infarction in rats. Each bar represents
mean ± SEM (n= 8). *Signiﬁcantly different from the normal group at p< 0.05. @Signiﬁcantly different from the isoprenaline group at
p< 0.05. #Signiﬁcantly different from the atorvastatin-treated group at p< 0.05.
38 M.A. Zaafan et al.generation, and an accumulation of cellular debris. Phagocyto-
sis of the resultant cellular debris by macrophages and neutro-
phils triggers the inﬂammatory cytokines as TNF-a.20 The
anti-inﬂammatory cytokines as IL-10 are also produced and
tend to modulate the inﬂammatory pathways, an effect that
is supported by a previous report by Pasqui et al.21
An elevation in cardiac NO content (expressed as nitrite)
was observed in the present study after isoprenaline injection.
Endothelium-derived NO is widely recognized as a mediator ofvasodilatation with important anti-inﬂammatory and anti-
thrombotic properties.22 In macrophages and several other cell
types, inﬂammatory mediators increase NO production via
activation of iNOS. High levels of NO production via iNOS
are associated with dilated cardiomyopathy and congestive
heart failure.23 Indeed, isoprenaline was demonstrated to in-
crease iNOS expression in rats.24
ECG monitoring of isoprenaline-treated rats showed
positive T wave and ST segment elevation coupled with
Table 1 Effect of oral atorvastatin, quercetin, and their combination on the cardiac contents of malondialdehyde (MDA), reduced
glutathione (GSH), and nitrite in isoprenaline-induced myocardial infarction in rats.
Groups MDA (nmol/g wet tissue) GSH (mg/g wet tissue) Nitrite (lmol/mg wet tissue)
Normal (saline; s.c.) 116.08 ± 3.20 13.33 ± 0.73 7.83 ± 0.28
Isoprenaline (100 mg/kg; s.c.) 161.71* ± 6.44 7.62* ± 0.61 20.45* ± 0.38
Atorvastatin (10 mg/kg) 133.25@ ± 6.65 9.47* ± 0.30 25.95*,@ ± 0.60
Quercetin (50 mg/kg) 127.30@ ± 7.30 10.93*,@ ± 0.31 15.55*,@,# ± 0.43
Atorvastatin + quercetin 132.47@ ± 2.87 10.80*,@ ± 0.39 13.18*,@,# ± 0.48
Each value represents mean ± SEM (n= 8).
* Signiﬁcantly different from normal group at p< 0.05.
@ Signiﬁcantly different from isoprenaline group at p< 0.05.
# Signiﬁcantly different from atorvastatin-treated group at p< 0.05.
Table 2 Effect of oral atorvastatin, quercetin, and their combination on serum levels of C-reactive protein (CRP), tumor necrosis
factor-alpha (TNF-a), and interleukin-10 (IL-10) in isoprenaline-induced myocardial infarction in rats.
Groups CRP (lg/ml) TNF-a (pg/ml) IL-10 (pg/ml)
Normal (saline; s.c.) 1.54 ± 0.04 82.55 ± 1.69 85.97 ± 3.38
Isoprenaline (100 mg/kg; s.c.) 2.89* ± 0.20 134.22* ± 6.14 128.15* ± 10.20
Atorvastatin (10 mg/kg) 2.02@ ± 0.09 104.73*,@ ± 3.27 87.94@ ± 7.09
Quercetin (50 mg/kg) 1.88@ ± 0.03 96.59@ ± 3.77 104.52 ± 9.28
Atorvastatin + quercetin 1.77@ ± 0.09 90.24@ ± 2.01 80.10@ ± 4.08
Each value represents mean ± SEM (n= 8).
* Signiﬁcantly different from the normal group at p< 0.05.
@ Signiﬁcantly different from the isoprenaline group at p< 0.05.
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induced myocardial ischemia and infarction. ECG pattern
alterations by isoprenaline were previously demonstrated by
previous investigators.19,25 Histopathologic examination of
isoprenaline-treated rats revealed inﬁltration of inﬂammatory
cells along with myocyte degeneration. These results are in
accordance with previous studies.4,13,16 These observations
along with the present biochemical changes in cardiac enzymes
and cytokines level conﬁrm the severity of myocardial injury.
Pretreatment with atorvastatin (10 mg/kg) attenuated the
cardiac damage caused by isoprenaline. The drug decreased
ST-segment elevation with marked increase in R-wave ampli-
tude. Atorvastatin also produced a signiﬁcant decrease in ser-
um cTn-I level. The current results support those of other
investigators who reported a cardioprotective effect of atorva-
statin.19,26,27 Atorvastatin changes in ECG and cardiac en-
zymes were coupled by a reduction in lipid peroxidation in
heart tissue through the signiﬁcant decrease in heart MDA
content. Similar results were reported by Mahfouz and
Kummerow.28
Pretreatment with atorvastatin showed also a marked de-
crease in the serum levels of CRP, TNF-a, and IL-10 which
could be attributed to atorvastatin documented anti-inﬂamma-
tory properties.6,29,30 Moreover, atorvastatin protective effects
in MI may be mediated by the modulation of ﬁbrinolysis by
reducing the levels of plasminogen activator inhibitor-1.19
These changes were coupled with a signiﬁcant increase in car-
diac nitrite content. Previous studies demonstrated the ability
of statins to upregulate eNOS activity and NO production
by increasing eNOS mRNA stability.31,32
Pretreatment with quercetin (50 mg/kg) produced a marked
protection against isoprenaline-induced myocardial damage.Indeed, the suppression of MI by quercetin was reﬂected in
the current investigation through the suppression of ST-seg-
ment elevation and the marked increase in R wave amplitude
upon ECG monitoring as compared to the isoprenaline group.
These results are in agreement with previous studies.25,33 In
addition, quercetin decreased the serum CK-MB activity and
cTn-I level when compared to the isoprenaline group. These
ﬁndings are in harmony with previous reports.34–36
Moreover, results of the current study reﬂected the ability
of quercetin to ameliorate isoprenaline-induced changes in oxi-
dative stress biomarkers, which is in agreement with the work
of previous investigators.33,36 These results are in harmony
with previous reports which stated that the biological actions
of quercetin are, in part, connected to its anti-oxidant proper-
ties which are mainly due to its ability to scavenge ROS and to
chelate transition metal ions.35,37 Moreover, quercetin protec-
tive effects could be also related to its ability to maintain heart
calcium content and prevent isoprenaline-induced increase in
heart calcium.38 The present ﬁndings were coupled by a reduc-
tion in cardiac nitrite content. A possible explanation for the
decrease in NO production by quercetin may be mediated by
its ability to inhibit iNOS expression through inhibition of nu-
clear factor-kappa B pathway, which further accounts for its
anti-inﬂammatory potential.10
The anti-inﬂammatory effect of quercetin was apparent by
the marked decrease in serum levels of CRP and TNF-a, which
is in agreement with previous studies.9,39 On the other hand,
quercetin mono-therapy failed to produce a signiﬁcant
decrease in serum IL-10 level. Further studies may be required
to explain this matter.
In the current study, pretreatment with atorvastatin and
quercetin together showed marked cardioprotective effects re-
Figure 3 Effect of oral atorvastatin (10 mg/kg), quercetin (50 mg/kg), and their combination on cardiac histopathologic changes in
isoprenaline-induced myocardial infarction in rats. (A) Section in a normal rat showing normal architecture of the heart tissue, being
composed of muscle cells, cardiomyocytes (my), with one centrally placed nucleus; (B) Isoprenaline control rat showing multiple focal
areas of myocardial cell degeneration (d) with edema (o) and inﬂammatory cells inﬁltration; (C) Atorvastatin-treated rat showing edema
with mild inﬂammatory cells inﬁltration in focal manner at the myocardium; (D) Quercetin-treated rat showing a noticeable preservation
from the deleterious effects of isoprenaline; (E) Atorvastatin + quercetin-treated rat showing a decrease in focal areas of edema and
inﬂammatory cells inﬁltration as compared to the isoprenaline control rat.
40 M.A. Zaafan et al.ﬂected by decreased serum cTn-I level, improved ECG altera-
tions coupled by decreased oxidative stress and all inﬂamma-
tory markers. Histopathologic examination of cardiac tissues
correlated with the observed biochemical and ECG changes.
Such effects can be explained by previously reported anti-oxi-
dant and anti-inﬂammatory potentials of both quercetin and
atorvastatin that were more apparent upon their combination
together.6,9,28,365. Conclusions
In conclusion, the present study revealed that quercetin and
atorvastatin pretreatment attenuated oxidative stress and
inﬂammatory reactions as well as declined tissue damage in
isoprenaline-induced MI in rats. Further experimental and
clinical studies may be needed to verify the cardioprotective ef-
fects of atorvastatin and quercetin.6. Conﬂict of interest
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